| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Newly identified loci that influence lipid concentrations and risk of coronary artery disease.
|
Nat Genet
|
2008
|
25.83
|
|
2
|
Common variants at 30 loci contribute to polygenic dyslipidemia.
|
Nat Genet
|
2008
|
20.66
|
|
3
|
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
|
Lancet
|
2003
|
13.69
|
|
4
|
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
|
Lancet
|
2011
|
13.10
|
|
5
|
Effects of extended-release niacin with laropiprant in high-risk patients.
|
N Engl J Med
|
2014
|
9.25
|
|
6
|
Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
|
N Engl J Med
|
2009
|
8.73
|
|
7
|
Large-scale association analysis identifies new risk loci for coronary artery disease.
|
Nat Genet
|
2012
|
7.59
|
|
8
|
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
|
Lancet
|
2004
|
5.19
|
|
9
|
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
|
Lancet
|
2010
|
4.23
|
|
10
|
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
|
Lancet
|
2005
|
4.20
|
|
11
|
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
|
JAMA
|
2010
|
3.34
|
|
12
|
Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization'.
|
Int J Epidemiol
|
2006
|
2.68
|
|
13
|
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
|
BMJ
|
2006
|
2.67
|
|
14
|
Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men.
|
Arch Intern Med
|
2007
|
2.55
|
|
15
|
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
|
Nature
|
2013
|
2.46
|
|
16
|
Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype.
|
Lancet
|
2003
|
2.40
|
|
17
|
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes.
|
Diabetes
|
2011
|
2.21
|
|
18
|
Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
|
Eur Heart J
|
2012
|
1.75
|
|
19
|
Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies.
|
Int J Epidemiol
|
2003
|
1.73
|
|
20
|
Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk.
|
Int J Epidemiol
|
2004
|
1.59
|
|
21
|
No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
|
J Am Coll Cardiol
|
2011
|
1.36
|
|
22
|
Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias.
|
PLoS Med
|
2012
|
1.27
|
|
23
|
N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
|
J Am Coll Cardiol
|
2007
|
1.22
|
|
24
|
Biomarkers of inflammation predict both vascular and non-vascular mortality in older men.
|
Eur Heart J
|
2008
|
1.22
|
|
25
|
Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study.
|
PLoS Genet
|
2006
|
1.16
|
|
26
|
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
|
BMC Clin Pharmacol
|
2009
|
1.01
|
|
27
|
Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
|
Circ Cardiovasc Genet
|
2011
|
0.92
|
|
28
|
Effect of temperature and light on the stability of fat-soluble vitamins in whole blood over several days: implications for epidemiological studies.
|
Int J Epidemiol
|
2004
|
0.89
|
|
29
|
The exon 1-8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction in 6946 cases and 2720 controls from a United Kingdom population.
|
Eur J Hum Genet
|
2008
|
0.79
|
|
30
|
Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults.
|
J Am Coll Cardiol
|
2016
|
0.77
|
|
31
|
Reply to Garrard and Jacoby and Smith et al.
|
Am J Clin Nutr
|
2015
|
0.75
|
|
32
|
Risk prediction for cardiovascular disease using ECG data in the China kadoorie biobank.
|
Conf Proc IEEE Eng Med Biol Soc
|
2016
|
0.75
|